Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The potential role of cellular therapies and vaccines in the future treatment of MPNs

Srdan Verstovsek • 28 Sep 2022
SOHO 2022
Myeloproliferative Neoplasms Antibodies Vaccines

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the excitement around the potential use of cellular therapies and vaccines in myeloproliferative neoplasms (MPNs), highlighting the possibility of targeting the calreticulin (CALR) mutation, and providing more effective treatment options for patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Srdan Verstovsek

1:52
An update on the use of navtemadlin in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
2:19
Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis
Srdan Verstovsek • 7 Dec 2022
2:19
FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek • 7 Dec 2022
1:56
Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera
Srdan Verstovsek • 7 Dec 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals